Patents by Inventor F. Anthony Romero

F. Anthony Romero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11203587
    Abstract: Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: December 21, 2021
    Assignee: TERNS, INC.
    Inventors: Thorsten A. Kirschberg, Randall Halcomb, Yingzi Xu, F. Anthony Romero
  • Patent number: 11168070
    Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: November 9, 2021
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
  • Patent number: 11155557
    Abstract: Compounds of Formula (IA), or a pharmaceutically acceptable salt thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: October 26, 2021
    Assignee: Genentech, Inc.
    Inventors: F. Anthony Romero, Mark Zak, Guiling Zhao, Paul Gibbons, Wei Li, Yun-Xing Cheng, Po-Wai Yuen, Limin Cheng
  • Publication number: 20210179564
    Abstract: Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: February 17, 2021
    Publication date: June 17, 2021
    Applicant: Genentech, Inc.
    Inventors: James John Crawford, Mark Zak, Terry Kellar, Yun-Xing Cheng, Wei Li, F. Anthony Romero, Paul Gibbons, Guiling Zhao, Gregory Hamilton, Simon Charles Goodacre
  • Publication number: 20210179626
    Abstract: Compounds of Formula I and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: February 12, 2021
    Publication date: June 17, 2021
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, F. Anthony ROMERO, Po-wai YUEN, Emily J. HANAN
  • Patent number: 10919911
    Abstract: Provided herein are compounds, preferably ASK1 inhibitor compounds, compositions thereof, and methods of their preparation, and methods of inhibiting ASK1 and methods for treating disorders mediated by ASK1.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: February 16, 2021
    Assignee: TERNS, INC.
    Inventors: Yingzi Xu, Randall Halcomb, Thorsten A. Kirschberg, F. Anthony Romero
  • Patent number: 10889571
    Abstract: Provided herein are compounds of formula (I) or formula (Ia) that inhibit tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: January 12, 2021
    Assignee: Terns, Inc.
    Inventors: F. Anthony Romero, Thorsten A. Kirschberg, Randall Halcomb, Yingzi Xu
  • Publication number: 20200399274
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: June 16, 2020
    Publication date: December 24, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G.M. Shore, F. Anthony Romero, Marian C. Bryan
  • Publication number: 20200399244
    Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R—R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: May 28, 2020
    Publication date: December 24, 2020
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
  • Publication number: 20200352951
    Abstract: Methods of using compounds and salts thereof as JAK kinase inhibitors are described herein, including methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: July 28, 2020
    Publication date: November 12, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, F. Anthony ROMERO, Yun-Xing CHENG
  • Patent number: 10800767
    Abstract: Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: October 13, 2020
    Assignee: Terns, Inc.
    Inventors: Thorsten A. Kirschberg, Randall Halcomb, Yingzi Xu, F. Anthony Romero
  • Publication number: 20200270248
    Abstract: Compounds of Formula (I) and (II), or a stereoisomer, tautomer, solvate, prodrug or salt thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: May 8, 2020
    Publication date: August 27, 2020
    Applicant: Genentech, Inc.
    Inventors: Simon Charles GOODACRE, Mark ZAK, F. Anthony ROMERO, Yun-Xing CHENG, Limin CHENG, Rongbao HUA
  • Patent number: 10696655
    Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: June 30, 2020
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
  • Patent number: 10689416
    Abstract: The proteasome inhibitors of this invention include peptide-based compounds with a short linear sequence of amino acids. An oxo or thio group is attached to the N-terminal amino acid. A protein-reactive electrophilic group such as an epoxyketone, an aziridinylketone, or a beta-lactone is attached to the C-terminal amino acid. Upon contact with a proteasome complex in a target cell, the electrophilic group reacts with a functional group in or near a binding pocket or active site of the proteasome, forming a covalent bond and thereby inactivating the proteasome. These and other proteasome inhibitors can be screened for binding affinity and an ability to selectively eliminate senescent cells or cancer cells. Compounds that selectively remove senescent cells can be developed for the treatment of conditions such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: June 23, 2020
    Assignee: Unity Biotechnology, Inc.
    Inventors: Ryan Hudson, Anne-Marie Beausoleil, F. Anthony Romero, Remi-Martin Laberge
  • Publication number: 20200115362
    Abstract: Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
    Type: Application
    Filed: October 10, 2019
    Publication date: April 16, 2020
    Inventors: Thorsten A. KIRSCHBERG, Randall HALCOMB, Yingzi XU, F. Anthony ROMERO
  • Publication number: 20200087283
    Abstract: Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease.
    Type: Application
    Filed: September 17, 2019
    Publication date: March 19, 2020
    Applicant: Terns, Inc.
    Inventors: F. Anthony ROMERO, Thorsten A. KIRSCHBERG, Randall HALCOMB, Yingzi XU
  • Publication number: 20200062779
    Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: October 30, 2019
    Publication date: February 27, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, F. Anthony ROMERO, Yun-Xing CHENG, Wei LI
  • Publication number: 20200062742
    Abstract: Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
    Type: Application
    Filed: August 23, 2019
    Publication date: February 27, 2020
    Inventors: Thorsten A. KIRSCHBERG, Randall HALCOMB, Yingzi XU, F. Anthony ROMERO
  • Publication number: 20200002346
    Abstract: Compounds of Formula I and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: September 5, 2019
    Publication date: January 2, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, F. Anthony ROMERO, Po-wai YUEN, Emily J. HANAN
  • Publication number: 20200002378
    Abstract: The proteasome inhibitors of this invention include peptide-based compounds with a short linear sequence of amino acids. An oxo or thio group is attached to the N-terminal amino acid. A protein-reactive electrophilic group such as an epoxyketone, an aziridinylketone, or a beta-lactone is attached to the C-terminal amino acid. Upon contact with a proteasome complex in a target cell, the electrophilic group reacts with a functional group in or near a binding pocket or active site of the proteasome, forming a covalent bond and thereby inactivating the proteasome. These and other proteasome inhibitors can be screened for binding affinity and an ability to selectively eliminate senescent cells or cancer cells. Compounds that selectively remove senescent cells can be developed for the treatment of conditions such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis.
    Type: Application
    Filed: August 12, 2019
    Publication date: January 2, 2020
    Inventors: Ryan Hudson, Anne-Marie Beausoleil, F. Anthony Romero, Remi-Martin Laberge